Last reviewed · How we verify
NCT01542866
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
NA trial testing Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) in 160 participants. Completed in 30 November 2011.
30 November 2011
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 160 |
| Start date | 11 January 2011 |
| Primary completion | 30 November 2011 |
| Estimated completion | 30 November 2011 |
| Sites | 23 locations across United States |
Drugs / interventions tested
- Health Management Tool (HMT)
Conditions studied
- Age Related Macular Degeneration (AMD) — all drugs for Age Related Macular Degeneration (AMD) →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Eligibility, any sex, with Age Related Macular Degeneration (AMD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular Degeneration (AMD) to detect a potential change in disease status.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration.
Keane PA, de Salvo G, Sim DA, Goverdhan S, et al · · 2015 · cited 43× · PMID 25733802 · DOI 10.2147/opth.s59012
Verify or expand the search:
- PubMed search for NCT01542866
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age Related Macular Degeneration (AMD)
Currently open trials in the same condition.
- NCT05932069 — Active AMD Study to Improve Function in Veterans · NA · recruiting
- NCT03349801 — Development of Novel Clinical Endpoints in Intermediate AMD · active not recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01542866 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 12 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01542866.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing